The Cancer Letter

Inside information on cancer research and drug development

Clinical

Researchers: Cabazitaxel Functions Differently Than Other Taxanes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Researchers found that a newer member of the taxane family, cabazitaxel, has properties that could make it more effective for some prostate cancer patients.

Researchers also found a genomic marker that could help physicians identify which patients might benefit most from cabazitaxel.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login

Site license subscribers:
Log in with your IP | Register a sponsored account